Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Speaker Hastert adds health policy advisor

Executive Summary

House Energy & Commerce Committee Chief Health Counsel Chuck Clapton joins the office of Speaker Dennis Hastert (R-Ill.) as policy adviser for healthcare and social security issues. Clapton was with the E&C Committee when Billy Tauzin, now CEO of PhRMA, served as chairman. Clapton has supported FDA, even when the agency faced strong criticism from others for its handling of drug safety. Following the COX-2 inhibitor fallout on Capitol Hill, Clapton stated that FDA was doing a "very good job" and that there was no need for "sweeping or comprehensive reforms" (1"The Pink Sheet" April 11, 2005, p. 15)...

You may also be interested in...



Senate HELP committee adds staffer

Sen. Mike Enzi, R-Wyo., ranking member of the Senate Health, Education, Labor and Pensions Committee, announces Chuck Clapton has joined the committee's minority staff as health policy director. His previous experience includes extensive work in the drug reimbursement area. Clapton most recently served as chief health counsel for Republican staff of the House Ways and Means Committee after working as a health care policy advisor for former Speaker Dennis Hastert, R-Ill. (1"The Pink Sheet," April 3, 2006, In Brief). He also served as health counsel to then House Energy & Commerce Committee Chair Billy Tauzin, R-La., during the drafting of the Medicare Modernization Act

Bextra On Capitol Hill: FDA’s “Turning Point” Or Another Sign Of Failure?

FDA's request for Pfizer to withdraw the COX-2 inhibitor Bextra could signal a new era of strong decision making at FDA, Senate Finance Committee Chairman Charles Grassley (R-Iowa) declared

COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel